Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO …

HJ Burstein, MR Somerfield, DL Barton… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
被引用次数：174 相关文章

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO …

HJ Burstein, MR Somerfield, DL Barton… - Journal of Clinical …, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> To update recommendations of
the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer …

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO …

HJ Burstein, MR Somerfield… - Journal of …, 2021 - mdanderson.elsevierpure.com
PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO …

HJ Burstein, MR Somerfield, DL Barton… - Journal of clinical …, 2021 - iro.uiowa.edu
PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …

Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO …

HJ Burstein, MR Somerfield, DL Barton, A Dorris… - sussex.figshare.com
PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
[HTML] ascopubs.org

[HTML][HTML] Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer …

HJ Burstein, MR Somerfield, DL Barton… - Journal of Clinical …, 2021 - ascopubs.org
Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal
Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update | Journal …

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO …

HJ Burstein, MR Somerfield, DL Barton… - Journal of Clinical …, 2021 - europepmc.org
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal
Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update …

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO …

HJ Burstein, MR Somerfield… - Journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. Methods An Expert Panel …

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO …

HJ Burstein, MR Somerfield, DL Barton… - Journal of Clinical …, 2021 - profiles.wustl.edu
PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
[HTML] nih.gov

[HTML][HTML] Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer …

HJ Burstein, MR Somerfield, DL Barton… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human
Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline …